Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma.
A phase II study of etoposide (VP16-213) in hepatocellular carcinoma was conducted among 18 Chinese patients. There was no observable tumour response but the treatment was relatively well tolerated with an overall median survival interval of 74 days.